COMPASS Pathways plc (NASDAQ:CMPS) Receives $21.83 Consensus Target Price from Brokerages

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $20.20.

A number of analysts have weighed in on the company. Canaccord Genuity Group decreased their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of COMPASS Pathways in a report on Tuesday, March 4th. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research report on Wednesday, January 15th.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors and hedge funds have recently bought and sold shares of CMPS. Polar Asset Management Partners Inc. grew its holdings in shares of COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after acquiring an additional 258,000 shares in the last quarter. Walleye Capital LLC bought a new stake in COMPASS Pathways in the third quarter worth about $2,126,000. Geode Capital Management LLC raised its position in COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock worth $266,000 after acquiring an additional 25,970 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in COMPASS Pathways by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after acquiring an additional 26,787 shares during the last quarter. Finally, Brown University grew its position in shares of COMPASS Pathways by 194.6% during the 4th quarter. Brown University now owns 214,200 shares of the company’s stock valued at $810,000 after acquiring an additional 141,500 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Price Performance

COMPASS Pathways stock opened at $2.83 on Friday. The stock’s 50 day moving average is $3.80 and its 200 day moving average is $4.62. COMPASS Pathways has a one year low of $2.69 and a one year high of $10.31. The firm has a market cap of $262.26 million, a P/E ratio of -1.29 and a beta of 2.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). As a group, research analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.